c-MYC-Induced Genomic Instability
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
MYC dysregulation initiates a dynamic process of genomic instability that is linked to tumor initiation.Early studies using MYC-carrying retroviruses showed that these viruses were potent transforming agents.Cell culture models followed that addressed the role of MYC in transformation.With the advent of MYC transgenic mice, it became obvious that MYC deregulation alone was sufficient to initiate B-cell neoplasia in mice.More than 70% of all tumors have some form of c-MYC gene dysregulation, which affects gene regulation, microRNA expression profiles, large genomic amplifications, and the overall organization of the nucleus.These changes set the stage for the dynamic genomic rearrangements that are associated with cellular transformation.G enomic instability is an enabling feature of cancer cells (Hanahan and Weinberg 2011).MYC is one of its drivers and will be reviewed in this article from its early days to the present.Special focus will be given to MYC's ability to induce genomic instability and DNA damage at multiple levels, its ability to remodel the architecture of a cell's nucleus, and ultimately, its ability to promote neoplasia. EARLY DAYS OF MYCTumor virology, which paved the way for the discovery of oncogenes, began in 1909 with F. Peyton Rous' isolation of the Rous sarcoma virus (Rous 1910(Rous , 1911)).His "discovery of tumor-inducing viruses" was rewarded with the Nobel Prize in Physiology or Medicine in 1966.In 1989, the Nobel Prize was awarded to J.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 1×
“Early studies implicated MYC in cell proliferation (Palmieri et al. 1983), but it was insufficient for cellular transformation unless it cooperated with a second oncogene, RAS, to transform primary embryo fibroblasts (Land et al. 1983, 1986).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · cited 2×
“Forexample, inhibiting CHK1/CHK2 (proteins activated by ATR that in turn activate cell-cycle checkpoints, replication fork progression, and anti-apoptotic activity) (Cimprich and Cortez 2008; López-Contreras and Fernandez-Capetillo 2010) increases DNA damage, the DDR, apoptosis, and, ultimately, cell death in human ca…”
BackgroundReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“Specifically, they showed that the tumor viruses carried a gene derived from cellular DNA that when captured by the virus became an oncogene or cancer-causing gene (Stehelin et al. 1976).”
BackgroundLinks between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876 · cited 4×
“It has the ability to mediate DNA damage, as first described by Vafa et al. (2002).”
BackgroundInfluentialA role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM
Sun, Y., Jiang, X., Chen, S., Fernandes, N., & Price, B. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504211102 · Cited by 738 · cited 2×
“TIP60, which plays a role in the ATM DDR by inducing acetylation of ATM in response to DNA damage (Sun et al. 2005), was proposed to be a haplo-insufficient tumor suppressor for pre- or early-stage lymphomas.”
BackgroundHIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408 · cited 1×
“It was also observed in hypoxic conditions in multiple tumor cell lines that the promoters of MSH2 and MLH1 changed from being occupied by MYC/MAX to MAX/MAD1 and MAX/MNT complexes (Bindra and Glazer 2007; see Hurlin 2013 and Conacci-Sorrell et al. 2014 for a description of the MXD/MNT proteins).”
BackgroundGlobal Regulation of Nucleotide Biosynthetic Genes by c-Myc
Liu, Y.-C., Li, F., Handler, J., Huang, C. R. L., Xiang, Y., Neretti, N., Sedivy, J. M., Zeller, K. I., & Dang, C. V. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002722 · Cited by 317 · cited 1×
“Liu et al. (2008) show this in multiple systems; chromatin immunoprecipitation with paired-end ditag sequencing analysis on a immortalized B-lymphocyte cell line, followed by qPCR on the products, showed that many genes involved in de novo nucleotide synthesis had E boxes in their promoters or…”
BackgroundDirect role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells
Mannava, S., Grachtchouk, V., Wheeler, L. J., Im, M., Zhuang, D., Slavina, E. G., Mathews, C. K., Shewach, D. S., & Nikiforov, M. A. (2008) · Cell Cycle · doi:10.4161/cc.6390 · Cited by 257 · cited 1×
“Also, when MYC was inhibited through lentivirus-based shRNAs in human metastatic melanoma cell lines, the genes encoding enzymes important for dNTP metabolism were repressed and the amount of dNTPs were reduced (Mannava et al. 2008).”
BackgroundCole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133 · cited 1×
“…activity) (Cimprich and Cortez 2008; López-Contreras and Fernandez-Capetillo 2010) increases DNA damage, the DDR, apoptosis, and, ultimately, cell death in human cancer cell lines and in the Em-MYC mouse model of lymphoma (Cole et al. 2011; Ferrao et al. 2011; Höglund et al. 2011a,b).”
Background
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Anti-c-myc RNAi-Based Onconanotherapeutics
Habib, S., Ariatti, M., & Singh, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120612 · Cited by 23
Metadata
- Authors
- Kuzyk, A., & Mai, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-04-01
- Volume
- 4
- Issue
- 4
- Pages
- a014373-a014373
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2102979288
- Cited by
- 124
- References
- 17
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.